Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

被引：0

作者：

San Miguel, Jesus F. ^{[1
]}

Schlag, Rudolf ^{[2
]}

Khuageva, Nuriet K. ^{[3
]}

Dimopoulos, Meletios Athanasios ^{[4
]}

Shpilberg, Ofer ^{[5
]}

Kropff, Martin ^{[6
]}

Spicka, Ivan ^{[7
]}

Petrucci, Maria T. ^{[8
]}

Palumbo, Antonio ^{[9
]}

Samoilova, Olga S. ^{[10
]}

Dmoszynska, Anna ^{[11
]}

Abdulkadyrov, Kudrat M. ^{[12
]}

Delforge, Michel ^{[13
]}

Jiang, Bin ^{[14
]}

Mateos, Maria-Victoria ^{[1
]}

Anderson, Kenneth C.

Esseltine, Dixie-Lee ^{[16
]}

Liu, Kevin ^{[17
]}

Deraedt, William M. ^{[18
]}

Cakana, Andrew Z. ^{[19
]}

van de Velde, Helgi ^{[18
]}

Richardson, Paul G. ^{[15
]}

机构：

[1] Hosp Clin Univ, Salamanca, Spain

[2] Praxisklin Dr Schlag, Wurzburg, Germany

[3] SP Botkin Moscow City Clin Hosp, Moscow, Russia

[4] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[5] Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel

[6] Univ Munster, Munster, Germany

[7] Charles Univ Prague, Prague, Czech Republic

[8] Univ Roma La Sapienza, Rome, Italy

[9] Univ Turin, Div Hematol, Myeloma Unit, AOU S Giovanni Battista, Turin, Italy

[10] Nizhnii Novgorod Reg Clin Hosp, Novgorod, Russia

[11] Med Univ Lublin, Lublin, Poland

[12] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia

[13] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium

[14] Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China

[15] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[16] Millennium Pharmaceut Inc, Cambridge, MA USA

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Beerse, Belgium

[19] Janssen Res & Dev, High Wycombe, Bucks, England

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：221 / 222

页数：2

共 11 条

[1] Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
San Miguel, Jesus F.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria Teresa
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Delforge, Michel
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie-Lee
Liu, Kevin
Deraedt, William
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 448 - 455
[2] Bortezomib Plus Melphalan-Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan-Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use
Mateos, Maria-Victoria
Richardson, Paul G.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria Teresa
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Esseltine, Dixie-Lee
Liu, Kevin
Cakana, Andrew Z.
van de Velde, Heigi
San Miguel, Jesus F.
BLOOD, 2009, 114 (22) : 1484 - 1485
[3] SUPERIOR EFFICACY WITH BORTEZOMIB PLUS MELPHALAN-PREDNISONE (VMP) VERSUS MELPHALAN-PREDNISONE (MP) ALONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM): RESULTS OF THE PHASE III MMY-3002 VISTA STUDY
San-Miguel, J.
Schlag, R.
Khuageva, N.
Dimopoulos, M.
Shpilberg, O.
Kropff, M.
Spicka, I.
Petrucci, M.
Palumbo, A.
Samoilova, O.
Dmoszynska, A.
Abdulkadyrov, K.
Schots, R.
Jiang, B.
Mateos, M.
Anderson, K.
Esseltine, D.
Liu, K.
Cakana, A.
Van de Velde, H.
Richardson, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 192 - 193
[4] Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma
Miguel, Jesus F. San
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin H.
Spicka, Ivan
Petrucci, Maria Teresa
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie-Lee
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul
BLOOD, 2008, 112 (11) : 242 - 242
[5] Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study
Mateos, Maria-Victoria
Richardson, Paul G.
Shi, Hongliang
Niculescu, Liviu
Elliott, Jennifer
Dow, Edward
van de Velde, Helgi
San Miguel, Jesus F.
BLOOD, 2013, 122 (21)
[6] Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Mateos, Maria-Victoria
Richardson, Paul G.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T.
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Esseltine, Dixie L.
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
San Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2259 - 2266
[7] Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
Palumbo, Antonio
Bringhen, Sara
Rossi, Dmide
Cavalli, Maide
Ria, Roberto
Gentilini, Silvia
Patriarca, Francesca
Nozzoli, Chiara
Levi, Anna
Guglielmelli, Tommasina
Benevolo, Giulia
Vincelli, Donatella
Baldini, Luca
Morabito, Fortunato
Grasso, Mariella
Marasca, Roberto
Rizzo, Manuela
Pautasso, Chiara
Falcone, Antonietta Pia
Gottardi, Daniela
Montefusco, Vittorio
Musolino, Caterina
Cangialosi, Clotilde
Mansueto, Giovanna
Liberati, Anna Marina
Magarotto, Valeria
Omede, Paola
Musto, Pellegrino
Petrucci, Maria Teresa
Boccadoro, Mario
BLOOD, 2012, 120 (21)
[8] PROLONGED THERAPY WITH BORTEZOMIB PLUS MELPHALAN-PREDNISONE (VMP) RESULTS IN IMPROVED QUALITY AND DURATION OF RESPONSE IN THE PHASE III VISTA STUDY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM)
Palumbo, A.
Schlag, R.
Khuageva, N.
Shpilberg, O.
Dimopoulos, M.
Kropff, M.
Spicka, I.
Petrucci, M.
Delforge, M.
Mateos, M.
Esseltine, D.
Liu, K.
Deraedt, W.
Van de Velde, H.
Richardson, P.
San-Miguel, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 83 - 83
[9] Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression
Lopez, Aurelio
Valero, Marta
Lorenzo, Jose Ignacio
Mateos, Maria-Victoria
Oriol, Albert
Joaquin, Martinez
Perez, Montserrat
Martinez, Rafael
de Paz, Raquel
Granell, Miguel
De Arriba, Felipe
Blanchard, M. Jesus
Javier Penalver, Francisco
Bello, Jose Luis
Martin, Maria Luisa
Bargay, Joan
Blade, Joan
Lahuerta, Juan Jose
San Miguel, Jesus F.
De La Rubia, Javier
BLOOD, 2013, 122 (21)
[10] Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
Maria-Victoria Mateos
Albert Oriol
Joaquín Martínez-López
Ana-Isabel Teruel
Enrique Bengoechea
Luis Palomera
Felipe de Arriba
Dixie-Lee Esseltine
Andrew Cakana
Lixia Pei
Helgi van de Velde
Jesus San Miguel
Annals of Hematology, 2016, 95 : 2033 - 2041

← 1 2 →